Context Therapeutics (CNTX) Change in Account Payables (2020 - 2026)
Context Therapeutics' (CNTX) quarterly Change in Account Payables came in at -$67158.0 in Q1 2026, up 84.58% year-on-year from -$36383.4 in Q1 2025, and up 64.28% quarter-over-quarter from -$187989.0 in Q4 2025.
Context Therapeutics (CNTX) Change in Account Payables (2020 - 2026) Analysis & Trends
Context Therapeutics has disclosed Change in Account Payables across 7 years of filings, most recently posting -$67158.0 for Q1 2026.
- Change in Account Payables for Q1 2026 came in at -$67158.0, up 84.58% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 million (up 240.26% YoY), and the FY2025 annual result was $1.1 million, up 215.84% from the prior year.
- Change in Account Payables came in at -$67158.0 for Q1 2026 at Context Therapeutics, up from -$187989.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $1.4 million in Q2 2025 to a low of -$1.5 million in Q2 2024.
- The 5-year median for Change in Account Payables is -$9372.0 (2022), against an average of $43618.0.
- Across the five-year window, Change in Account Payables surged 199.38% in 2023 and plunged 7519.08% in 2024, its largest moves.
- Context Therapeutics' Change in Account Payables stood at -$558665.0 in 2022, then surged by 199.38% to $555208.0 in 2023, then dropped by 26.47% to $408253.0 in 2024, then plunged by 146.05% to -$187989.0 in 2025, then jumped by 64.28% to -$67158.0 in 2026.
- The last three Change in Account Payables figures came in at -$67158.0 (Q1 2026), -$187989.0 (Q4 2025), and $324996.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | -3.26 Mn |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 35.60 Mn |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -9.42 Mn |
| 10 | Context Therapeutics | 166.57 Mn | 166.57 Mn | - | -67,158.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -67,158.00 |
| Mar 31, 2026 | -67,158.00 |
| Dec 31, 2025 | -187,989.00 |
| Dec 31, 2025 | -187,989.00 |
| Sep 30, 2025 | 324,996.00 |
| Sep 30, 2025 | 324,996.00 |
| Jun 30, 2025 | 1.39 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | -435,637.00 |
| Mar 31, 2025 | -435,637.00 |
| Dec 31, 2024 | 408,253.00 |
| Dec 31, 2024 | 408,253.00 |
| Sep 30, 2024 | 461,786.00 |
| Sep 30, 2024 | 461,786.00 |
| Jun 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.48 Mn |
| Mar 31, 2024 | -337,652.00 |
| Mar 31, 2024 | -337,652.00 |
| Dec 31, 2023 | 555,208.00 |
| Dec 31, 2023 | 555,208.00 |